We are delighted to announce that John C. Byrd, MD, has joined the Oncology Times team as Clinical Advisory Editor for Hematology/Oncology. He is the D. Warren Brown Chair of Leukemia Research and Professor of Medicine, Medicinal Chemistry, and Veterinary Biosciences and Director of the Division of Hematology at The Ohio State University.
Dr. Byrd's translational research has resulted in the identification of several therapeutic agents active in chronic lymphocytic leukemia and related leukemias and lymphomas, including rituximab, ibrutinib, alemtuzumab, and flavopiridol.
He is an active member of both the American Society of Clinical Oncology and the American Society of Hematology, as well as several clinical trials groups. He was recently elected to the American Society of Clinical Investigation and as a Fellow of the American Association for the Advancement of Science. He was chosen as a University Distinguished Scholar at OSU in 2008; is on the editorial board of several journals including Blood and the Journal of Clinical Oncology; and has authored or co-authored more than 300 peer-reviewed publications.
In addition, as he notes on the OSU website, despite his passion for clinical and translational research, his favorite day of the week is Monday, when he spends 8-12 hours in clinic providing active care for patients.